Nuvectis Pharma (NVCT) AI Stock Analysis

• Market Cap: $228.62M
• Dividend Yield: N/A
• Average Volume (3M): 89.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: N/A
• EPS Growth: -16.26%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.31
• Shares Outstanding: 26,491,701
• 10 Day Avg. Volume: 112,705
• 30 Day Avg. Volume: 89,483
• PEG Ratio: -0.33
• Price to Book (P/B): 8.94
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.29
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -7.03
• 1Y Price Target: $15.67
• Price Target Upside: 85.22% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $9.00 ▲(6.38% Upside)
• Action: Reiterated Date: 02/12/26
• Date: Action: Reiterated 02/12/26

The score is held back primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn implying continued external funding risk). Technicals are a meaningful positive with price above key moving averages and positive momentum, but valuation remains constrained by negative earnings and no stated dividend yield.

Positive Factors

Conservative balance sheet

Zero reported debt and materially improved equity reduce leverage risk and preserve financial flexibility. Over 2–6 months this structural conservatism lowers bankruptcy risk, supports partnership or licensing discussions, and gives management optionality when raising capital or timing dilutive financing.

Focused precision oncology pipeline

A targeted pipeline aimed at genetically defined cancers supports clearer patient selection and potentially faster, biomarker-driven clinical development. Structurally, this focus can improve trial success odds, attract strategic partners, and create durable value if lead programs advance toward registrational milestones.

Rebuilt equity and asset base

Material improvement in equity and a tangible asset base provide a stronger financial cushion versus prior years. This supports continued R&D spending and operating needs in the medium term, reducing immediate insolvency risk and improving the company's ability to execute development plans or secure non-dilutive funding.

Negative Factors

No revenue

Absence of any revenue is a durable constraint on financial self-sufficiency and makes the company fully dependent on external financing. Over months this limits visibility into commercialization timing, reduces operating cash coverage, and increases the strategic urgency to achieve clinical milestones or secure partner funding.

Sustained cash burn

Consistent negative operating and free cash flow (~-$16M in 2025) implies ongoing funding needs and potential dilution risk. Structurally, sustained cash burn pressures management to raise capital before revenue generation, which can constrain long-term R&D sequencing and negotiation leverage with partners or investors.

Widening net losses

Sharply widening losses over multi-year periods reflect increasing development costs without offsetting revenue or milestone receipts. This persistent negative profitability erodes equity over time if unchanged, raising the probability of future capital raises and limiting reinvestment capacity absent program de-risking.

Nuvectis Pharma Business Overview & Revenue Model

Company Description

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

How the Company Makes Money

Nuvectis Pharma makes money primarily through the development and commercialization of its proprietary cancer therapies. The company's revenue model includes licensing agreements, partnerships with other pharmaceutical companies, and potentially the sale of its products upon receiving regulatory approval. Nuvectis Pharma may also generate income through milestone payments and royalties from its collaborations and partnerships. The company's earnings are significantly influenced by its ability to successfully bring drug candidates to market, navigate complex regulatory environments, and establish strategic alliances with key stakeholders in the healthcare industry.

Nuvectis Pharma Financial Statement Overview

Summary

Income statement and cash flow are weak with no revenue (2020–2025), widening losses (net loss ~-$28.9M in 2025), and persistent negative operating/free cash flow (~-$16.0M in 2025). The key offset is a conservative balance sheet with $0 debt and rebuilt positive equity (~$18.4M in 2025), reducing leverage risk but not solving ongoing funding needs.

Income Statement

The company reports no revenue across 2020–2025 annual periods, which is common for early-stage biotech but limits earnings quality and visibility. Losses are persistent and have generally widened, with net loss moving from about $12.9M (2021) to about $28.9M (2025). With no revenue base, profitability remains structurally negative and improvement is not yet evident in the reported results.

Balance Sheet

Balance sheet leverage is conservative with total debt reported at $0 across the periods shown, reducing financial risk. Stockholders’ equity improved materially from negative in 2020–2021 to positive levels in 2022–2025 (about $18.4M in 2025), supporting the asset base (about $31.7M in 2025). However, returns remain weak given ongoing losses, and equity value can still be pressured if cash burn continues without offsetting funding or commercialization progress.

Cash Flow

Cash generation remains a key weakness: operating cash flow and free cash flow are consistently negative, indicating ongoing cash burn to fund operations (about -$16.0M in 2025 vs. -$12.2M in 2024). While the cash burn improved versus 2023 (about -$16.0M in 2025 vs. -$16.0M in 2023), it worsened year-over-year from 2024 to 2025, highlighting funding dependence. Overall cash flow profile suggests continued need for external capital until revenue begins.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-27.57M	-19.00M	-22.90M	-19.23M	-12.89M
Net Income	-26.44M	-19.00M	-22.26M	-19.09M	-12.89M
Balance Sheet
Total Assets	31.71M	18.61M	19.18M	20.41M	6.66M
Cash, Cash Equivalents and Short-Term Investments	31.63M	18.53M	19.13M	19.99M	5.74M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	13.30M	8.89M	6.98M	6.19M	17.66M
Stockholders Equity	18.41M	9.71M	12.20M	14.22M	-11.01M
Cash Flow
Free Cash Flow	-16.01M	-12.25M	-15.95M	-13.56M	-9.50M
Operating Cash Flow	-16.01M	-12.25M	-15.95M	-13.56M	-9.50M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	29.11M	11.65M	15.09M	27.81M	15.25M

Nuvectis Pharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8.46
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVCT, the sentiment is Neutral. The current price of 8.46 is below the 20-day moving average (MA) of 8.60, above the 50-day MA of 8.26, and above the 200-day MA of 7.43, indicating a neutral trend. The MACD of 0.13 indicates Positive momentum. The RSI at 49.21 is Neutral, neither overbought nor oversold. The STOCH value of 37.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NVCT.

Nuvectis Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVCT	52 Neutral	$228.62M	-6.63	-158.88%	―	―	-16.26%
OBIO	52 Neutral	$225.86M	-2.19	-166.97%	―	6.46%	-14.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NKTX	47 Neutral	$158.40M	-1.70	-26.69%	―	―	25.84%
PYXS	45 Neutral	$85.30M	-0.96	-87.28%	―	-82.53%	-52.00%
MOLN	42 Neutral	$188.37M	-2.62	-49.86%	―	-100.00%	11.02%